Taiwan Salt Aims to Match 2025 Profit Level by 2026, to Continue Investing in Packaged Water Products

The Asia Biotech Congress and Exhibition is being held from today (16th) to the 19th at Taipei Nangang Exhibition Center, Hall 1. Taiwan Salt (1737-TW) hosted a new product launch event for 'Lü Mi Ya' on the first day of the exhibition. Regarding its full-year outlook for 2026, Taiwan Salt stated that while the first half of this year was impacted by international conflicts and rising raw material costs, which eroded operating performance, the outlook for the second half is relatively optimistic. The company aims to match its 2025 full-year profit level as a baseline and strives for even better performance, while continuing to invest in its packaged water business.

In 2025, Taiwan Salt achieved a post-tax net profit of NT$399 million, representing a 7.63% year-on-year increase, with earnings per share (EPS) of NT$2.00. The shareholders' meeting approved a dividend payout of NT$1.40 per share.

In terms of revenue structure, the seawater and marine chemical division—particularly salt and water—remains the company's core, accounting for over 80% of total revenue. The water business, in particular, has benefited from strong momentum and has achieved over a decade of consecutive rapid growth.

To address production capacity constraints arising from the continued growth of the water business, Taiwan Salt plans to invest NT$300–500 million annually over the next 3–5 years into its primary production facility, the Tongxiao Plant, for equipment upgrades and the introduction of new machinery. General Manager Li Jiehan noted that recent labor shortages and rising material prices have significantly increased construction costs—projects that previously cost NT$100–200 million now face doubled expenses. As a result, capital expenditures and construction projects will be advanced cautiously.

In the biotechnology and skincare segment, Taiwan Salt had previously aimed to increase its revenue contribution to 30%. However, due to the rapid growth of the water business and slower-than-expected physical store expansion post-pandemic, the biotech product line's share of total revenue has slightly declined.

Chairman Ding Yen-che emphasized that Taiwan Salt has accumulated over 20 years of collagen R&D expertise and continues to lead innovation as 'the pioneer of collagen.' The company applies collagen technology broadly across health supplements, beauty skincare, and cleansing products, establishing an integrated capability from raw material development and process design to market applications. Its self-developed non-denatured type II collagen has attracted international customers for three consecutive years, demonstrating Taiwan Salt's technological strength and global competitiveness, and helping advance Taiwan's biotech innovations into international markets.

Additionally, Taiwan Salt is actively revitalizing its idle assets and investing in green energy development. Its installed rooftop and ground-mounted solar power systems generate stable electricity daily, bringing in approximately NT$20–30 million in fixed annual revenue. The company plans to fully develop its remaining idle assets for green energy applications.